Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Scl
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- AVP-923
What it measured
Main measures
emotional control
Who could take part
MS (type not specified) · 18 to 68
Show the full criteria
Inclusion criteria
* 18 to 68 years of age * Confirmed diagnosis of Multiple Sclerosis * Clinical history of pseudobulbar affect
Exclusion criteria
* Sensitivity to quinidine or opiate drugs * Recent diagnosed within 2 months with Multiple Sclerosis * Patient on anti-depressants * Patient with liver or kidney disease * Patient with hypotension
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying out of proportion. Other terms used to describe this condition include emotional lability, emotionalism, emotion incontinence, emotional discontrol, excessive emotionalism and pathological laughing and crying. AVP-923 is a new experimental drug that may assist in the reduction of uncontrolled episodes. This study will test the safety and efficacy of AVP-923 in the treatment of MS patients suffering from pseudobulbar affect.
Papers
Loading reviews and guidelines…
History
Started
Dec 2002
Main results due
Jun 2004
Finished
Jun 2004